FOR IMMEDIATE RELEASE
Salt Lake City, UT (June 4, 2018) – Biomerics LLC, a medical device contract manufacturer headquartered in Salt Lake City, UT is pleased to announce the acquisition of FutureMatrix Interventional, Inc. FMI, located in Athens, TX specializes in the design and manufacture of interventional catheters for the cardiovascular and urology markets.
“We are pleased to add FMI’s capabilities to the Biomerics portfolio,” stated Travis Sessions, CEO. “We welcome the FMI team to the group, and look forward to their contribution. This acquisition expands our capabilities and important customer relationships. We look forward to investing in and expanding the business for our customers, employees, and community. Combining FMI with Biomerics’ existing medical device business establishes Biomerics as a leader in the attractive minimally invasive interventional segment of the medical device market”.
FMI, founded in 1993 by James Passmore, began business by developing percutaneous transluminal angioplasty (PTA) catheters for the treatment of peripheral artery disease. Over the years, the company expanded its PTA balloon technologies and developed other peripheral vascular, kidney stone management, and urology catheters. Today, the FDA registered location includes over 50,000 sq. ft. of manufacturing space and employs more than 400 employees.
Biomerics, with over 1100 employees, operates seven facilities located in Utah, Minnesota, Indiana, Costa Rica, and Texas. Founded in 2009, Biomerics has grown into a market leader in the minimally invasive interventional catheter market. Biomerics provides engineered components to the medical device market including biomaterials, extrusions, molded parts, laser processed parts, machined parts, balloons, and reinforced shafts. Additionally, it supplies packaged sterile medical devices including advanced interventional catheters, surgical tools, and vascular access products.
Biomerics specializes in the design, development, and production of medical devices for diagnostic and interventional procedures for the cardiovascular, structural heart, cardiac rhythm management, and vascular access markets. The company, formed in 2009, provides a full range of engineered components and finished devices to the world’s leading medical device OEMs.
Aden Hirtle, Marketing Communications Manager